| Date | | Title |
| Dec 15, 2009 |  | Seattle Genetics and Millennium: The Takeda Oncology Company Announce Strategic Collaboration for Novel Late Stage Lymphoma Program Brentuximab Vedotin (SGN-35) |
| Dec 08, 2009 | | The Addition of Velcade® (Bortezomib) for Injection to Novel Combination Delivers Promising Results in Patients With Non-Hodgkin’s Lymphoma |
| Dec 06, 2009 | | Velcade® (Bortezomib) for Injection Based Combinations Deliver Two-Year Overall Survival Rates of Up To 88 Percent In Patients Wwth Previously Untreated Multiple Myeloma |
| Dec 05, 2009 | | Velcade® (Bortezomib) For Injection Based Regimens Result In Lower Costs And Less Patient Burden Than Other Commonly Used Multiple Myeloma Treatment Regimens |
| Dec 01, 2009 | | Millennium Launches Interactive Website Of Award-Winning Cancer Initiative |
| Nov 30, 2009 | | Velcade® (Bortezomib) for Injection To Be Featured In Plenary Session at American Society of Hematology |
| Nov 18, 2009 | | Millennium Initiates First Clinical Trial with The First Oral Proteasome Inhibitor |
| Oct 21, 2009 | | Millennium Initiates Phase II Trial For Diffuse Large B-Cell Lymphoma |
| Oct 01, 2009 | | Millennium Moves Up Ranking Of Top 10 Biopharma Companies In The World By Science Magazine |
| Sep 18, 2009 | | FDA Grants Priority Review Status to Supplement Containing Long-Term Survival Data for Velcade® (Bortezomib) for Injection |
| Sep 11, 2009 | | Millennium Initiates Phase II Trial of Prostate Cancer Compound |
| Sep 02, 2009 | | FDA To Review Supplement Containing Long-Term Survival Data for Velcade® (Bortezomib) For Injection |
| Jul 07, 2009 | | CBP501 Enters Phase II Trials for the Treatment of Non-Small Cell Lung Cancer |
| May 31, 2009 | | In Clinical Trials Velcade® (Bortezomib) for Injection as a Foundation of Therapy Continues to Deliver Significant Response Rates in Previously Untreated Multiple Myeloma Patients |
| May 31, 2009 | | The Addition of Velcade® (Bortezomib) for Injection to New and Standard Combinations Delivers Promising Results in Patients with Non-Hodgkin’s Lymphoma |
| May 31, 2009 | | Data Presented on Two Novel Millennium Investigational Oncology Drugs at ASCO |
| May 19, 2009 | | Velcade® (Bortezomib) For Injection And Pipeline Data To Be Highlighted At American Society Of Clinical Oncology Annual Meeting |
| Apr 14, 2009 | | Millennium To Present Oncology Pipeline Data At Annual American Association For Cancer Research Meeting |
| Apr 08, 2009 | | Nature Publishes Pre-Clinical Data On An Inhibitor Of A Novel Target Discovered By Millennium |
| Apr 06, 2009 | | Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Millennium |
| Mar 23, 2009 | | Dr. Nancy Simonian Delivers Keynote At Oncology Summit In Boston |
| Mar 03, 2009 | | Millennium Initiates Two Phase Il Trials Of Novel Aurora A Kinase Inhibitor |
| Feb 23, 2009 | | Data On Velcade® (Bortezomib) For Injection Based Therapies To Be Presented At The International Myeloma Workshop |
| Feb 11, 2009 | | Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial |
